ThomasAlexanderRadoMDPhD

Oncology • Kennewick, WA

Physician

Join to view full profile

Dr. Rado is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rado's full profile

Already have an account?

Office
7360 W Deschutes Ave
Kennewick, WA 99336
Phone+1 509-783-0144

Fax+1 509-783-8244

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1980 - 1983
University of Arkansas For Medical Sciences College of MedicineClass of 1977

Certifications & Licensure

WA State Medical License 1995 - 2026
AL State Medical License 1984 - 1995
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer Start of enrollment: 2008 Apr 23
Completed
Phase 2
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
Completed
Phase 2
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
Observational Registry Study of Quality of Life When Treating BTcP With Abstral Start of enrollment: 2013 Oct 01
Completed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm Start of enrollment: 2014 Jun 01
Completed
Not Applicable
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

36 citations
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Jeffrey R. Infante, Tony R. Reid, Allen Lee Cohn, William Jeffery Edenfield, Terrence P. Cescon
Cancer. 2013-07-15
13 citations
PU.1 regulates the expression of the human neutrophil elastase gene.
Sampathkumar Srikanth, Thomas A. Rado
Biochimica Et Biophysica Acta. 1998-06-16
19 citations
A 30-base pair element is responsible for the myeloid-specific activity of the human neutrophil elastase promoter.
Sampathkumar Srikanth, T. A. Rado
The Journal of Biological Chemistry. 1994-12-23

Grant Support

Expression Of Granule Constituents In Human MyelopoiesisNational Cancer Institute1987–1989

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member